Related Experiment Videos
[Treatment of obstetric cholestasis with polyunsaturated phosphatidylcholine and ursodeoxycholic acid]
Beata Marciniak1, Zaneta Kimber-Trojnar, Bozena Leszczyńska-Gorzelak
1Katedra i Klinika Poloinictwa i Perinatologii Uniwersytetu Medycznego w Lublinie.
Insights
This study on obstetric cholestasis found that higher bile acid levels correlate with earlier diagnosis and more severe outcomes. Combined therapy with UDCA and PPC may be beneficial, especially for early-onset or severe cases.
Area of Science:
- Obstetrics and Gynecology
- Hepatology
- Perinatal Medicine
Background:
- Obstetric cholestasis is a serious pregnancy complication characterized by elevated bile acids.
- Understanding the relationship between bile acid levels and obstetric outcomes is crucial for timely intervention.
- Current treatment strategies for obstetric cholestasis vary, necessitating research into optimal therapeutic approaches.
Purpose of the Study:
- To analyze obstetric outcomes and laboratory results in relation to pre-treatment serum bile acid (BA) levels in patients with obstetric cholestasis.
- To compare the efficacy of different treatment regimens (PPC, UDCA, or combination) based on BA levels.
- To investigate the correlation between BA levels and indicators of cholestasis severity and pregnancy progression.
Main Methods:
- A cohort of 43 pregnant women diagnosed with obstetric cholestasis was divided into three groups based on pre-treatment serum bile acid (BA) levels (11-15, 15-20, and >20 micromol/L).
- Group I received polyunsaturated phosphatidylcholine (PPC), Group II received ursodeoxycholic acid (UDCA), and Group III received a combination of UDCA and PPC.
- Maternal serum levels of transaminases, alkaline phosphatase, bilirubin, and bile acids were measured before treatment and during delivery. Cord blood BA levels were also assessed.
Main Results:
- No significant differences were observed in patient age, parity, delivery method, birth weight, or Apgar scores across groups.
- The group with the highest pre-treatment bile acid levels (>20 micromol/L) exhibited the earliest diagnosis of obstetric cholestasis.
- This severe group also showed earlier pregnancy termination, higher pre-treatment transaminases and bile acids, and greater fluctuations in these markers compared to the lowest BA group.
Conclusions:
- Combined therapy with UDCA and PPC appears to be a promising treatment option for obstetric cholestasis.
- This combined approach may be particularly beneficial in cases of early-onset or severe obstetric cholestasis.
- Further research is warranted to confirm the efficacy and optimal use of combined UDCA and PPC therapy.
Objective:
Analysis of obstetric outcomes and laboratory results depending on blood serum level of bile acids (BA) in patients with obstetric cholestasis before treatment.
Material And Methods:
The study was conducted among 43 pregnant women with obstetric cholestasis. The study population was divided into 3 groups, depending on blood serum level of bile acids before treatment: I group (n = 15)--BA 11-15 micromol/l, II group (n = 13)--BA 15-20 micromol/1 and III group (n = 15)--BA > 20 micromol/. Polyunsaturated phosphatidylcholine (PPC) treatment was used in I group, ursodeoxycholic acid (UDCA) in II group and combination of them in III group. Blood serum levels of transaminases, alkaline phosphatase and bilirubin were determined before treatment and during delivery Bile acids concentrations were also assessed during delivery in maternal serum and cord blood.
Results:
No significant statistical difference was observed in patients age, number of primiparas, delivery method, neonatal birth weight and Apgar score. The earliest obstetric cholestasis diagnosis was observed in III group. Earlier pregnancy termination, higher transaminases and bile acids levels before treatment, larger differences (A) of transaminases and bile acids levels before treatment and during delivery as well as larger A in bile acids levels before treatment and in cord blood during delivery were observed in III group in comparison to I group.
Conclusions:
It seems that combined therapy with UDCA and PPC could be considered in obstetric cholestasis, especially in case of its early onset and/or severe course.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Cholecystitis
Synthesis of Phosphatidylcholine in the ER Membrane
The major components of all eukaryotic cell...
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Pharmaceutical Poisoning: Treatment Strategies
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...